Newsletter

2/6/2015

Imaging3, Inc. Announces 2015 Outlook and Updates.

Imaging3™, Inc. announces today that it has entered into an agreement with the accountants and advisors of the firm Rose, Snyder & Jacobs LLP, with the goal of bringing Imaging3’s SEC financial reports current and obtaining a trading symbol through FINRA so that it can reemerge as a publicly traded company. Dane Medley, Chairman/CEO of Imaging3, commented, “While we cannot assure that Imaging3 will be successful in reemerging as a public company, the engagement of a new outside accounting firm represents an important step in our path to reemergence.”

Imaging3 also announces that its Board of Directors ratified the proposed acquisition and stock purchase of a California-based privately owned rental company that caters to the Medical and B2B marketplace. The transaction has been agreed to verbally by both parties and is currently expected to be completed during the first quarter of 2015. Imaging3 will announce the name of the company as soon as it is permitted to do so under the parties’ nondisclosure agreement. Medley commented, “We are working to develop share value for the company with a new business model and are pursuing several strategic acquisitions and other business transactions in 2015. Our objective is to continue adding value towards our core competencies while enhancing and broadening our product and service offerings.

Imaging3 has recently become the exclusive EnvisionTEC dealer for California for professional grade 3D printers and FDA approved medical bio plotters. EnvisionTEC is becoming a world leader in 3D printer manufacturing specializing in rapid prototyping and equipment, across a variety of markets. Imaging3 will be launching a new marketing campaign in the near future, with more details on this exciting new opportunity. Mr. Medley commented “EnvisionTEC has an excellent track record and is growing it’s dealer base across the US. We are excited to be partnered with an up and coming leader in the 3D market space.”

Imaging3 is also completing software upgrades on the Dominion VI scanner, with a goal of resubmitting Imaging3’s 510(k) application to the Food and Drug Administration later this year. This process will be managed by an outside consulting firm to help expedite the FDA process. Medley stated, “We are excited at the developments and enhancements made to date as we progress towards reaching our goal of obtaining FDA approval.”

Inaging3’s Board of Directors has also accepted the resignation of Raul Carrega as a director of Imaging3. Medley commented, “Raul has been an asset to Imaging3 over the years and we wish him the best in his future endeavors. The Board is considering options for appointing a replacement.” Imaging3 will continue to provide ongoing updates in the form of filings and press releases, all of which can be found on our website, www.imaging3.com, under the news tab at the top of the page.

Sincerely,
Imaging3, Inc.
Burbank CA 91505
(800) 900-9729
info@imaging3.com
www.imaging3.com

About Imaging3

Imaging3, Inc., founded in 1993, has developed a medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company’s website at http://www.imaging3.com for more information

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, failure to obtain a trading symbol from FINRA, failure to consummate desired business combinations or transactions, delays or adverse rulings relating to its pending Chapter 11 bankruptcy action, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction, potential product liability claims, and other factors detailed in reports filed by the Company. Imaging3 has previously been unsuccessful in obtaining regulatory approval for the Dominion VI scanner and cannot assure that it will obtain regulatory approval for the Dominion VI scanner or any of its other products, obtain a trading symbol from FINRA, reemerge as a public company, complete any specific business acquisitions or transactions, or become profitable.